RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

May 9, 2023

Study Completion Date

May 23, 2024

Conditions
Mucopolysaccharidosis Type II (MPS II)
Interventions
GENETIC

RGX-121

Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette

Trial Locations (2)

94609

University of California San Francisco, Benioff Children's Hospital, Oakland

H4A 3J1

McGill University Heath Center, Montreal

All Listed Sponsors
lead

REGENXBIO Inc.

INDUSTRY